Abstract
Reply to “Mid-regional pro-adrenomedullin (MR-proADM): An even better prognostic biomarker than C reactive protein to predict short-term survival in patients with decompensated cirrhosis at risk of infection?”
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have